Quick Answer
Lyra Therapeutics, Inc. reported Total Revenue of $398.0 thousand for fiscal year 2025.
Lyra Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $398.0K -74.1% |
$1.53M -1.5% |
$1.56M +14.3% |
$1.36M +378.2% |
$285.0K | — |
| Revenue (ASC 606) | $398.0K -74.1% |
$1.53M -1.5% |
$1.56M +14.3% |
$1.36M +378.2% |
$285.0K | — |
| Net Income | -$28.92M +69.0% |
-$93.44M -49.1% |
-$62.68M -13.4% |
-$55.28M -27.0% |
-$43.51M -96.7% |
-$22.13M -35.7% |
| Diluted EPS | -$18.62 +74.0% |
-$71.75 -5594.4% |
-$1.26 +31.1% |
-$1.83 +45.4% |
-$3.35 | — |
| Total Assets | $36.11M -45.6% |
$66.35M -53.5% |
$142.60M +29.7% |
$109.97M +100.4% |
$54.87M -32.1% |
$80.83M +440.2% |
| Cash and Equivalents | $15.89M -60.8% |
$40.58M +81.5% |
$22.35M -31.3% |
$32.55M -28.8% |
$45.75M -38.7% |
$74.59M +660.5% |
| Stockholders Equity | -$10.72M -192.4% |
$11.59M -87.0% |
$89.42M +10.7% |
$80.75M +135.3% |
$34.32M -53.9% |
$74.49M +160.4% |
| R&D Expense | $18.41M -57.9% |
$43.77M -8.9% |
$48.03M +23.8% |
$38.80M +30.7% |
$29.69M +137.1% |
$12.52M +4.1% |
| Operating Income | -$31.02M +67.8% |
-$96.35M -43.5% |
-$67.12M -19.2% |
-$56.31M -29.1% |
-$43.62M -96.4% |
-$22.21M -34.4% |
| Shares Outstanding | 1.77M +35.5% |
1.31M -97.7% |
57.21M +79.8% |
31.83M +144.7% |
13.01M +0.6% |
12.93M +5501.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $25.0K | -87.2% | -86.3% |
| Revenue (ASC 606) | September 30, 2025 | $25.0K | -87.2% | -86.3% |
| Net Income | September 30, 2025 | -$5.98M | +49.6% | +19.5% |
| Diluted EPS | September 30, 2025 | -$3.38 | +62.7% | +38.7% |
| Total Assets | September 30, 2025 | $43.71M | -44.5% | -16.9% |
| Cash and Equivalents | September 30, 2025 | $22.05M | -7.3% | -26.0% |
| Stockholders Equity | September 30, 2025 | -$4.33M | -121.0% | -366.8% |
| R&D Expense | September 30, 2025 | $4.05M | -31.4% | -20.8% |
| Operating Income | September 30, 2025 | -$6.24M | +49.9% | +29.3% |
| Shares Outstanding | September 30, 2025 | 1.64M | -97.5% | +1.2% |
- Lyra Therapeutics, Inc. reported Total Revenue of $398.0 thousand for fiscal year 2025.
- Lyra Therapeutics, Inc. showed a decrease of -74.1% in Total Revenue compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported Revenue (ASC 606) of $398.0 thousand for fiscal year 2025.
- Lyra Therapeutics, Inc. showed a decrease of -74.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported Net Income of -$28.92 million for fiscal year 2025.
- Lyra Therapeutics, Inc. showed an increase of +69.0% in Net Income compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported Diluted EPS of $18.62 per share (loss) for fiscal year 2025.
- Lyra Therapeutics, Inc. showed an increase of +74.0% in Diluted EPS compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported Total Assets of $36.11 million for fiscal year 2025.
- Lyra Therapeutics, Inc. showed a decrease of -45.6% in Total Assets compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported Cash and Equivalents of $15.89 million for fiscal year 2025.
- Lyra Therapeutics, Inc. showed a decrease of -60.8% in Cash and Equivalents compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported Stockholders Equity of -$10.72 million for fiscal year 2025.
- Lyra Therapeutics, Inc. showed a decrease of -192.4% in Stockholders Equity compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported R&D Expense of $18.41 million for fiscal year 2025.
- Lyra Therapeutics, Inc. showed a decrease of -57.9% in R&D Expense compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported Operating Income of -$31.02 million for fiscal year 2025.
- Lyra Therapeutics, Inc. showed an increase of +67.8% in Operating Income compared to the prior fiscal year.
- Lyra Therapeutics, Inc. reported Shares Outstanding of 1.77 million shares for fiscal year 2025.
- Lyra Therapeutics, Inc. showed an increase of +35.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: